Back to Search VC Home Page
Venture Capital Search Engine
search over 1,000 Venture Capital related sites
Keywords about VC:  

5AM Ventures

1.5AM Ventures - Company Profile   (100%):
5AM Ventures makes seed and early-stage investments in next-generation life science companies. Founded in 2002 by former Bay City Capital principals, 5AM Ventures has offices in Boston and San Francisco. As successful former company leaders and established venture capitalists, the 5AM Team take a ha...
2.5AM Ventures - Company Profile   (97%):
5AM Ventures manages time to asset realization by selecting strategically varied life science companies, actively creating value in those companies, and knowing how and when to realize returns. Building on advanced technologies. The 5AM portfolio is a balanced selection of next-generation life scien...
3.5AM Ventures - Company Profile   (97%):
A diversified life sciences focus The 5AM portfolio comprises seed and early-stage investments with a leading-edge life science focus. Built around advanced technologies, our portfolio is diversified among companies driven by core science, established intellectual property, or near-term products. Ac...
4.5AM Ventures - Leadership - Partners   (87%):
Braughm W. Ricke Controller Mr. Ricke joined 5AM Ventures in 2004 and is responsible for the administration, financial reporting, and communication of all 5AM fund activities. Prior to joining 5AM Ventures, Mr. Ricke was Controller for Artiman Ventures, an early-stage information technology venture ...
5.5AM Ventures - Company Profile   (83%):
Venture capital is an interpersonal medium. As such, both network and teamwork are crucial. By drawing on the knowledge and resources of our friends and colleagues in the larger scientific and venture capital communities, we can better identify and grow leading-edge life science technologies. And by...
6.5AM Ventures - Company Profile   (81%):
To manage the considerable expense of building life science companies, 5AM Ventures first seeks opportunities that require less capital than, for example, marketed-product in-licensing companies, and then provides its portfolio companies with critical assistance in capital efficiency. Through a numb...
7.5AM Ventures - Company Profile   (74%):
SCOTT M. ROCKLAGE, Ph.D. JOINS 5AM VENTURES Biotech Veteran and Former CEO of Cubist Pharmaceuticals Brings Additional Senior Operating and Company Building Experience to 5AM Venture's Investment Team MENLO PARK, California -- October 16, 2003 - 5AM Ventures, a seed and early-stage venture capital f...
8.5AM Ventures - Company Profile   (57%):
December 22, 2003 BIOCENTURY - MIIKANA: THE MAGIC PATH November 4, 2003 MIIKANA THERAPEUTICS AND NOVIMMUNE SA SIGN STRATEGIC ALLIANCE FOR ANTIBODY DEVELOPMENT October 16, 2003 SCOTT M. ROCKLAGE, Ph.D. JOINS 5AM VENTURES October 7, 2003 SCOTT M. ROCKLAGE JOINS MIIKANA THERAPEUTICS AS EXECUTIVE CHAIRM...
9.5AM Ventures - Company Profile   (51%):
Symyx Therapeutics changes name to Ilypsa- appoints Dr. Scott M. Rocklage as Executive Chairman - moves to state-of-the-art 21,000 Square Feet R&D facility SANTA CLARA, California -- June 2, 2004 - Ilypsa Inc., a biopharmaceutical company formerly known as Symyx Therapeutics Inc. announced that Scot...
10.5AM Ventures - Leadership - Partners   (50%):
Kevin M. Forrest, PhD Associate Dr. Forrest joined 5AM Ventures in 2005 from Princeton University where he studied RNA-based regulatory processes in the lab of Dr. Elizabeth Gavis. While at Princeton, Dr. Forrest also served as a due diligence advisor to ProQuest Investments, a healthcare venture ca...
11.5AM Ventures - Leadership - Partners   (50%):
Andrew J. Schwab Founder and Managing Partner Prior to founding 5AM Ventures in 2002, Mr. Schwab was a Principal at Bay City Capital. After joining Bay City Capital in 1999, Mr. Schwab led many of the firm s investment and merchant banking activities for such companies as Cubist, Lombard Odier, Meta...
12.5AM Ventures - Leadership - Partners   (49%):
R. Andrew McMillan, PhD Associate Dr. McMillan joined 5AM Ventures in 2005 from NASA, where he was a Principal Investigator in the Bioengineering Branch and member of the Center for Nanotechnology at the Ames Research Center. Dr. McMillan s contributions to the nanotechnology field have resulted in ...
13.5AM Ventures   (46%):
Dedicated to active value creation in seed and early-stage life science companies, the 5AM Team take a diversified, leading-edge, and hands-on investment approach to company building and return realization.
14.5AM Ventures   (46%):
Dedicated to active value creation in seed and early-stage life science companies, the 5AM Team take a diversified, leading-edge, and hands-on investment approach to company building and return realization.
15.5AM Ventures - Sitemap   (43%):
Home Quick Facts Profile Team 5AM Partners John D. Diekman, PhD Scott M. Rocklage, PhD Andrew J. Schwab 5AM Professionals Carin M. Rollins R. Andrew McMillan, PhD Kevin M. Forrest, PhD Braughm W. Ricke Scientific Advisory Board Strategic Advisors Strategy Diversification Time to Realization Keys to ...
16.5AM Ventures - Leadership - Partners   (42%):
Scott M. Rocklage, PhD Managing Partner Dr. Rocklage joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. Dr. Rocklage has over 20 years of healthcare management experience with strategic leadership responsibilities that have resulted in the successful approval of ...
17.5AM Ventures - Leadership - Partners   (41%):
John D. Diekman, PhD Founder and Managing Partner Prior to founding 5AM in 2002, Dr. Diekman was a Founder, Managing Director, and Vice Chairman of Bay City Capital, a life science investment firm. Dr. Diekman has over 30 years of experience in the life science industry and built his career through ...
18.5AM Ventures - Company Profile   (36%):
KaloBios and Celscia Therapeutics Announce Merger Merger creates human antibody therapeutics company, combines rapid human antibody generation technology with experienced product R&D team and expands antibody pipeline. PALO ALTO, California -- January 12, 2004 - KaloBios and Celscia Therapeutics ann...
19.Institutional Venture Partners   (35%):
Samuel D. Colella A highly visible and respected venture capitalist, particularly for his leadership in life sciences investing, Sam Colella co-founded Versant Ventures following 20 years of successful operational roles in high technology industries and more than 17 years with Institutional Venture...
20.5AM Ventures - Company Profile   (35%):
AMBRX ASSEMBLES WORLD CLASS TEAM AND RAISES $12.5 MILLION TO APPLY BREAKTHROUGH TECHNOLOGY TO PROTEIN THERAPEUTICS SAN DIEGO, California -- September 22, 2003 - Ambrx, Inc., a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics, announced that Richard D. DiMarchi, P...

Page: 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20  

VC Directory: A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z   Others